The trial will enrol patients with mild symptoms of SARS-CoV-2 infection to evaluate the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of CT-P59
News
EU regulators approve Novartis’ breast cancer combo
Piqray in combination with fulvestrant is the first treatment for tumours with a PIK3CA mutation
NICE backs Bavencio combo for kidney cancer
The combination of an immunotherapy with a targeted antiangiogenic therapy offers patients a novel treatment option
Nirsevimab shows promise for long-term RSV protection
The monoclonal antibody is the first potential passive immunisation for infants to demonstrate sustained protection across the entire RSV season with a single dose
GSK sees dip in second-quarter sales
Sales decline in the second quarter reflects expected disruption from COVID-19
NICE rejects NHS funding for Kyowa Kirin’s Poteligeo
NICE is not recommending NHS funding for Kyowa Kirin’s Poteligeo (mogamulizumab) as a treatment for mycosis fungoides or Sézary syndrome for adults who have had at least one previous systemic treatment.
NHS People Plan to address new pandemic challenges
The plan sets out a new a new recruitment, retention and support package
EC approves subcutaneous version of Remsima
The SC formulation can be administered by patients themselves, reducing treatment time to approximately two-five minutes
New research to investigate higher COVID-19 risk among BAME groups
It is hoped that the six new projects, which total £4.3 million worth of funding, will further understanding on the link between ethnicity and susceptibility to the virus
AZ’ Farxiga hits all goals in chronic kidney disease trial
The drug significantly reduced the worsening of renal function or risk of death in patients with chronic kidney disease with and without type II diabetes
Sanofi/GSK sign deal with UK gov for COVID-19 vaccine
The companies have agreed to supply up to 60 million doses
PRIME status for Adaptimmune’s synovial sarcoma drug
The drug has the potential to address an unmet need
CHMP backs expanding scope of Kyowa Kirin’s Crysvita
The decision could see older adolescents and adults access the treatment for X-linked hypophosphataemia (XLH)
Pfizer and BioNTech select lead mRNA vaccine against COVID-19
The companies have started a global pivotal Phase II/III safety and efficacy study
AZ signs $6bn deal with Daiichi Sankyo
The move secures AZ access to the Japanese drug giant’s experimental antibody drug conjugate
